Abstract
Abstract Encouraging innovation by rewarding pharmaceutical patent holders is a key to societal progress, given mandatory disclosure and adequate reimbursement. Following debate on fair prices from a competition law perspective, the recent Health Trade Assessment Regulation provides Member States with a harmonized tool to help them set prices in a more sustainable way. This article discusses the extent to which the Regulation will provide comprehensive access to healthcare as an expression of patient welfare, framing the debate in terms of sustainability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
